Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Ownership & Trading Activity

Institutional holders, insider transactions, and congressional trades for ARQT. 13F holdings as of 2026-09-30.

In 13F filings for the quarter ended September 30, 2026, 208 institutions reported holding ARQT, with 78.8 million shares worth $2.1 billion in aggregate.

Top Institutional Holders

InstitutionSharesValueChange
BlackRock19,171,035$507MINCREASED
Vanguard9,796,992$259MINCREASED
State Street7,718,628$204MINCREASED
UBS Group5,533,053$146MINCREASED
Morgan Stanley5,296,532$140MINCREASED

Recent Insider Trades

InsiderTypeSharesValueDate
Masaru Matsuda (EVP, Chief Legal Officer)EXERCISE40,000$146K2026-11-04
Masaru Matsuda (EVP, Chief Legal Officer)SELL40,000$1M2026-11-04
Masaru Matsuda (EVP, Chief Legal Officer)EXERCISE40,000$146K2026-11-04
Todd Watanabe (Reporting Person's title: President and Chief Executive Officer)SELL4,377$139K2026-11-02
Patrick Burnett (EVP, Chief Medical Officer)SELL943$30K2026-11-02

Full institutional holdings, insider history, and congressional trades for Arcutis Biotherapeutics, Inc. Common Stock on SentiSense.